Mycobacteriophage Muddy_HRMN0052

Phase 1Biologic

VVancouver Coastal Health

Mycobacteriophage Muddy_HRMN0052 is one of 39 biologic programs targeting Abscess. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

AbscessPhase 1

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Abscess

#DrugCompanyPhaseTrials

Valtrex

GGlaxo Dba Glaxosmithkline

Approved

2 2

Duragesic

CCephalon

Approved

1 3

Flagyl

DDePuy Orthopaedics

Approved

1 4

Activase

Roche

Phase 3

1 5

Mycobutin

Pfizer

Phase 3

1 6

Biaxin

AbbVie

Phase 3

1 7

Primaxin

Pfizer

Phase 3

1 8

Sirturo

WWim Janssens

Phase 3

2 9

MS Contin

HHikma Pharmaceuticals LLC

Phase 3

1 10

Tygacil

PPrism Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Abscess1 trial

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection

Enrolling by invitation·VVancouver Coastal Health·Phase 1·NCT07228702·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mycobacteriophage Muddy_HRMN0052. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycobacteriophage Muddy_HRMN0052 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycobacteriophage Muddy_HRMN0052. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vancouver Coastal Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: VVancouver Coastal Health

Mycobacteriophage Muddy_HRMN0052

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Abscess1 trial

References

Drug Info

Quick Facts

Related News